Heron Therapeutics, Inc.

Point Biomedical Corporation

The Clorox Company

Other

University of Pittsburgh

Insite Vision Corporation

Soane Technologies, Inc.

Vitaphore Corporation

2c Optics, Inc.

Vitaphore Corporation C/o Integra Lifesciences Corp.

Thomas B Ottoboni

Han Han

Lee Ann Lynn Girotti

Ronald Kenichi Yamamoto

Robert E Short

Stanley R Conston

Lee Ann Lynn Schillinger

Gregory Van Buskirk

Young C Bae

David S Soane

Lyle M Bowman

David A Peterson

Boli Zhou

Rajesh A Patel

James D McManus

Alfred G Zielske

Steven A Bolkan

Lafayette D Foland

Barry D Quart

E Glenn Tickner

Charles B Ungermann

Joseph Niemann

Fredric J Lim

Lisa B Jungherr

Dale S Steichen

Thai Minh Nguyen

Kevin J Brodbeck

Suzanne M Thompson

Jeffrey D Gabe

Cris T Spillett

Donna L Tavares

Kwan Chan

Lee Ann Girotti

Cris Tina Spillett

Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release.

Compositions of a polyorthoester and an aprotic solvent

Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

Methods of use of emulsion formulations of aprepitant

Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

Methods of use of emulsion formulations of an NK-1 receptor antagonist

Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an organic acid excipient, and a basic drug are described, along with related methods.

Compositions of a polyorthoester and an organic acid excipient

Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents. The low viscosity delivery systems have a polyorthoester polymer, a polar aprotic solvent and a solvent containing a triglyceride viscosity reducing agent. Compositions described include an amide- or anilide-type local anesthetic of the 'caine' classification, and a non-steroidal anti-inflammatory drug (NSAID), along with related methods, e.g., for treatment of post-operative pain or for prophylactic treatment of pain. The compositions are suitable for delivery via, e.g., direct application and instillation, intradermal injection, subcutaneous injection, and nerve block (perineural).

Long-acting polymeric delivery systems

Emulsion formulations of an NK-1 receptor antagonist and uses thereof

Emulsion formulations of aprepitant

Growing community of inventors

Belmont, CA, United States of America

Thomas B Ottoboni